Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1133 of 6351
-
Can a year of sunitinib delay kidney Cancer's return after lung surgery?
Disease control Stopped earlyThe aim ist to identify biomarkers in the blood, to indicate early response or early treatment resistance.
Phase 2 • Sponsor: Association of Urologic Oncology (AUO) • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Half-Matched stem cell transplants get safer with new Cell-Sorting technique
Disease control Recruiting nowParticipants are being asked to take part in this study because treatment of his or her disease requires a stem cell transplant. Stem cells or "mother" cells are the source of normal blood cells and lead to recovery of blood counts after bone marrow transplantation. Unfortunately…
Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for aggressive brain tumors: avastin delivered directly to the brain
Disease control Recruiting nowThe high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all primary brain tumors in adults. This group of tumors also exhibits the most aggressive behavior, resulting in median overall survival durations of on…
Phase 1/2 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Weekly vs. Every-3-Weeks chemo: which works better for ovarian cancer?
Disease control OngoingThis phase III clinical trial studies two different dose schedules of paclitaxel to see how well they work in combination with carboplatin with or without bevacizumab in treating patients with stage II, III or IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New vaccine combo aims to outsmart relapsed neuroblastoma in kids
Disease control OngoingNeuroblastoma is the second most common solid tumor seen in children, but causes approximately 15% of childhood cancer deaths each year. Patients with high-risk disease require treatment with a combination of chemotherapy, surgery, radiation, and stem cell transplant; however, ma…
Phase 1/2 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Brain zaps plus nerve pulses: a new hope for stroke recovery?
Disease control CompletedRecent work showed that application of peripheral nerve and cortical stimulation independently can induce 10-15 % improvement in motor performance in patients with chronic stroke. The purpose of this study was to compare in post-stroke hemiplegic patients the effect on motor rec…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Major trial tests if newer drugs can replace stem cell transplants for myeloma
Disease control OngoingIn this research study, we are looking to explore the drug combination, lenalidomide, bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple…
Phase 3 • Sponsor: Paul Richardson, MD • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Bone marrow transplant breakthrough: more donors now possible for blood cancer patients?
Disease control CompletedIf transplantation using mismatched unrelated donors or non-first-degree relatives could be performed with an acceptable toxicity profile, an important unmet need would be served. Towards this goal, the current study extends our platform of nonmyeloablative, partially HLA-mismatc…
Phase 1/2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Cooling blankets tested to save newborn brains after oxygen loss
Disease control Stopped earlyThe Optimizing Cooling trial will compare four whole-body cooling treatments for infants born at 36 weeks gestational age or later with hypoxic-ischemic encephalopathy: (1) cooling for 72 hours to 33.5°C; (2) cooling for 120 hours to 33.5°C; (3) cooling for 72 hours to 32.0°C; an…
Sponsor: NICHD Neonatal Research Network • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Can a cement injection outperform a brace for spine fractures?
Disease control CompletedThe purpose of this protocol is to prove the efficacy of vertebroplasty in patients suffering from acute non osteoporotic vertebral compression fracture. Vertebroplasty consists in the injection of cement (PMMA) in the damaged vertebral body to prevent further collapse. Our stu…
Phase 3 • Sponsor: University Hospital, Clermont-Ferrand • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
10-Year study reveals how bariatric surgery impacts blood pressure and health
Disease control CompletedThis study is designed to understand how bariatric surgery affects patients with metabolic syndrome over both the short and long term. We will track changes in blood pressure and other health indicators for up to 10 years after surgery. The goal is to see whether surgery can prov…
Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 26, 2026 19:07 UTC
-
Personalizing leukemia drug doses could boost treatment success
Disease control CompletedImatinib mesylate (Gleevec/Glivec, IM) is currently the gold standard or CML-CP front line therapy. The recommended dose of IM is 400 mg/day. The rates of complete cytogenetic responses at 3, 6 and 12 months are 27%, 50% and 69% respectively. The optimal IM daily dose is not yet …
Phase 2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control Recruiting nowBackground: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lympho…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Engineered donor cells take aim at returning blood cancers
Disease control CompletedBackground: * Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a procedure that transplants bone marrow cells (stem cells) from a matching donor into a recipient in order to allow the donor stem cells to produce cells that will attack the recipient s cancer cells…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a Tumor's genes reveal the best treatment path?
Knowledge-focused Recruiting nowThis study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing. Gene expression profiles, mutational profiles, and transcript isoform-level data will be …
Sponsor: Lund University • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
New pill shows promise against tough prostate cancer
Disease control CompletedThe purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer. Patients will first be enrolled into Phase 1 of the study to identify a tolerable dose for the Phase 2 portion of the study. In the Phase 2, 3 diff…
Phase 1/2 • Sponsor: Aragon Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Head and neck cancer: which chemo combo works best?
Disease control OngoingThe goal of this clinical research study is to learn which chemotherapy combination is more effective in treating locally advanced head and neck squamous cell carcinoma. The side effects of these combinations will also be studied.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for kids with tough brain tumors: targeted drug shows promise
Disease control OngoingThis phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of t…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Can a Two-Drug combo beat back Tough-to-Treat hairy cell leukemia?
Disease control OngoingBackground: * Researchers are attempting to develop new treatments for hairy cell leukemia (HCL) that has not responded well to or has recurred after standard HCL therapies. One nonstandard treatment for HCL is rituximab, an antibody that binds to the cancer cells and helps the …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a gentle electric pulse ease chronic nerve pain?
Symptom relief CompletedPulsed RadioFrequency (PRF) is a relatively new technique derived from a well established and proven intervention, thermal radiofrequency (RF). Both procedures are used in the treatment of chronic pain. Unlike RF treatment, PRF does no direct damage to the nerve. During PRF treat…
Sponsor: McMaster University • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC